SMI closes nearly flat at 14,802.52 as pharma heavyweights weigh
Published on 11/02/2026 at 18:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSSMI ends nearly unchanged
- The SMI closed on November 2, 2026, at 14,802.52 points, down 0.05 percent from the previous session.
- Declines in Roche and Novartis offset broader gains, while falling oil prices supported economically sensitive shares.
- The SPI rose 0.10 percent and the SMIM gained 0.83 percent, highlighting the drag from the large pharmaceutical constituents.
The Swiss Market Index (SMI) ended Monday's SIX session nearly unchanged at 14,802.52 points. According to finanzen.ch, citing AWP, the blue-chip index fell 0.05 percent from its previous close. The session's close was therefore a marginal retreat rather than a broad-based sell-off.
Pharmaceutical heavyweights weigh
The main drag came from Roche and Novartis. The AWP market report said the two pharmaceutical heavyweights were held back by analyst downgrades, not by negative product or clinical-study news. Their influence was sufficient to limit the SMI despite a clear majority of constituents finishing higher. The report described the ratio of gainers to decliners as roughly three to one.
The contrast with broader Swiss benchmarks underlined the concentration effect. The SPI, which covers the wider Swiss equity market, rose 0.10 percent to 20,867.74 points. The SMIM, with less exposure to the SMI's largest constituents, advanced 0.83 percent to 3,230.94 points. These moves indicate that weakness in the index heavyweights was more decisive for the SMI than the general direction of the market.
Oil prices support cyclical shares
A sharp fall in oil prices provided a counterweight. The AWP report said the decline particularly benefited economically sensitive stocks, while a market participant described energy prices as the market's key indicator. The move came amid renewed hopes for diplomatic progress involving Iran and Qatar, which reduced immediate supply concerns in energy markets. The SMI nevertheless remained largely stable as investors weighed that support against pressure on Roche and Novartis.
For investors, the session illustrates why the capitalization-weighted SMI can diverge from the broader Swiss market. The index comprises Switzerland's 20 largest and most liquid equities, according to SIX. Movements in its largest healthcare constituents can therefore dominate the headline result even when participation across the market is positive.
Further SMI coverage is available on the SMI topic page.
